These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12380959)

  • 1. Erythropoietic agents as neurotherapeutic agents: what barriers exist?
    Jumbe NL
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):91-107. PubMed ID: 12380959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What evidence supports use of erythropoietin as a novel neurotherapeutic?
    Brines M
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):79-89. PubMed ID: 12380958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system frontiers for the use of erythropoietin.
    Olsen NV
    Clin Infect Dis; 2003; 37 Suppl 4():S323-30. PubMed ID: 14582001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor.
    Pankratova S; Kiryushko D; Sonn K; Soroka V; Køhler LB; Rathje M; Gu B; Gotfryd K; Clausen O; Zharkovsky A; Bock E; Berezin V
    Brain; 2010 Aug; 133(Pt 8):2281-94. PubMed ID: 20435631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of epoetin alfa on the central nervous system.
    Cerami A; Brines ML; Ghezzi P; Cerami CJ
    Semin Oncol; 2001 Apr; 28(2 Suppl 8):66-70. PubMed ID: 11395856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.
    Grasso G; Graziano F; Sfacteria A; Carletti F; Meli F; Maugeri R; Passalacqua M; Certo F; Fazio M; Buemi M; Iacopino DG
    Neurosurgery; 2009 Oct; 65(4):763-9; discussion 769-70. PubMed ID: 19834382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective properties of epoetin alfa.
    Cerami A; Brines M; Ghezzi P; Cerami C; Itri LM
    Nephrol Dial Transplant; 2002; 17 Suppl 1():8-12. PubMed ID: 11812906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword?
    Velly L; Pellegrini L; Guillet B; Bruder N; Pisano P
    Pharmacol Ther; 2010 Dec; 128(3):445-59. PubMed ID: 20732352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.
    Stasi R; Amadori S; Littlewood TJ; Terzoli E; Newland AC; Provan D
    Oncologist; 2005 Aug; 10(7):539-54. PubMed ID: 16079321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
    Chen G; Shi JX; Hang CH; Xie W; Liu J; Liu X
    Neurosci Lett; 2007 Oct; 425(3):177-82. PubMed ID: 17825990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors.
    Glaspy JA
    Oncology (Williston Park); 2003 Dec; 17(12):1724-30; discussion 1731-2, 1735, 1739. PubMed ID: 14723012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa.
    Banks WA; Jumbe NL; Farrell CL; Niehoff ML; Heatherington AC
    Eur J Pharmacol; 2004 Nov; 505(1-3):93-101. PubMed ID: 15556141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage.
    Juul S
    Acta Paediatr Suppl; 2002; 91(438):36-42. PubMed ID: 12477263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Erythropoietin--a new therapy in cerebral ischemia?].
    Kalialis LV; Olsen NV
    Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice.
    Sasu BJ; Hartley C; Schultz H; McElroy P; Khaja R; Elliott S; Egrie JC; Browne JK; Begley CG; Molineux G
    Acta Haematol; 2005; 113(3):163-74. PubMed ID: 15870486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: from bench to bedside.
    Ntaios G; Savopoulos C; Chatzinikolaou A; Hatzitolios AI
    Acta Neurol Scand; 2008 Dec; 118(6):362-6. PubMed ID: 18513348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in neuroprotection and neurotherapy.
    Smith RE
    J Support Oncol; 2004; 2(1):39-49. PubMed ID: 15330371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat.
    King VR; Averill SA; Hewazy D; Priestley JV; Torup L; Michael-Titus AT
    Eur J Neurosci; 2007 Jul; 26(1):90-100. PubMed ID: 17614942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.